NewAmsterdam Pharma

NewAmsterdam Pharma

NewAmsterdam Pharma was incorporated in 2019 in the Netherlands by John Kastelein, a vascular medicine specialist at the University of Amsterdam who spent his career studying CETP inhibition as a pathway to reduce cardiovascular risk. Kastelein previously led academic steering committees for drugs like torcetrapib and anacetrapib. When Amgen discontinued its CETP inhibitor AMG 899, Kastelein recognized that the compound — a potent, selective cholesteryl ester transfer protein inhibitor — had been abandoned for strategic reasons, not clinical failure. He acquired rights to the molecule and formed NewAmsterdam to carry it forward. The company operates out of Naarden and opened a US hub in Miami to access American capital markets and clinical infrastructure. NewAmsterdam's entire deployment model is a clinical-stage biotech strategy executed through public equity. The company pursues a single-asset clinical program — obicetrapib — across multiple Phase III cardiovascular outcomes trials: BROADWAY, BROOKLYN, TANDEM, and PREVAIL. It targets the vast statin-intolerant and heterozygous familial hypercholesterolemia populations who cannot meet LDL targets with existing therapies. The geographic footprint spans trial sites across North America, Western Europe, and Eastern Europe. The firm does not run a venture portfolio, direct co-investments, or fund-of-funds — all capital is allocated to trial execution, manufacturing scale-up with third-party CDMOs, and early commercialization preparation. The company has no disclosed co-investors in a fund structure; it raises through follow-on public offerings, including a $205 million raise in 2023 led by Frazier Healthcare Partners and Bain Capital Life Sciences, alongside existing holder Forbion (per the firm's SEC filings, 2023). NewAmsterdam has no assets under management in the traditional sense — it reports a cash and equivalents balance of approximately $750 million as of mid-2024, which it projects will fund operations through the anticipated Phase III readouts and toward a potential New Drug Application (per the firm's quarterly filings, 2024). The team is led by CEO Michael Davidson, an academic cardiologist and former Chief of Preventive Cardiology at the University of Chicago, reflecting the firm's clinical-trial-first orientation. The company went public on Nasdaq in 2022 through a business combination with a SPAC, raising $523 million (per the firm's S-1 and subsequent press releases, 2022). In November 2024, NewAmsterdam reported positive topline data from the BROADWAY trial, showing obicetrapib achieved a 33% placebo-adjusted LDL reduction at one year, positioning it for regulatory filings. The structural differentiator is the reverse venture capital model: Kastelein rescued a deprioritized pharma asset using scientific domain expertise and public-market capital rather than a traditional venture syndicate or family office backing. The company behaves like a single-asset biotech SPV but trades on Nasdaq with full public liquidity. Its succession and governance structure is straightforward — Davidson runs the development and regulatory strategy while Kastelein retains the scientific founder role, with no disclosed family office involvement, generational wealth transfer, or philanthropic carve-out vehicles. The firm's architecture is a direct bet on one molecule overcoming a class that pharmaceutical peers abandoned.